Teva Pharmaceutical Industries Limited (TEVA) DEF 14A19 Apr 23Definitive proxyFinancial data

Company Profile

Cover

Cover	12 Months Ended
Cover	Dec. 31, 2022
Document Information [Line Items]
Document Type	DEF 14A
Amendment Flag	false
Entity Information [Line Items]
Entity Registrant Name	TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Entity Central Index Key	0000818686

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($)	12 Months Ended
Pay vs Performance Disclosure - USD ($)	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Pay vs Performance Disclosure [Table]
Pay vs Performance [Table Text Block]	Pay Versus Performance Disclosure In Non-PEO Year Summary Compensation (1)(2)(3) Average Non-PEO Average Non-PEO (1)(2)(3) Value of Initial Net Non-GAAP ($ Millions) TSR Peer Group (a) (b) (c) (d) (e) (f) (g) (h) (i) 2022 15,529,138 17,214,057 3,977,166 4,426,020 93.06 123.43 (2,406 ) 4,139 2021 14,681,772 7,570,056 3,740,840 3,075,466 81.73 129.31 456 4,401 2020 15,724,518 10,866,321 3,997,258 3,783,167 98.47 114.32 (4,099 ) 4,388 (1) Kåre Schultz was our PEO for each year presented. The individuals comprising the Non-PEO 2020 2021 2022 Eli Kalif Eli Kalif Eli Kalif Dr. Hafrun Fridriksdottir Dr. Sven Dethlefs Dr. Sven Dethlefs Brendan O’Grady Eric Drapé Mark Sabag Eric Drapé Mark Sabag Eric Drapé (2) The amounts shown for Compensation Actually Paid have been calculated in accordance with Item 402(v) of Regulation S-K (3) Compensation Actually Paid reflects the exclusions and inclusions of certain amounts for the PEO and the Non-PEO Year Summary Compensation Exclusion of Stock Inclusion of Equity Compensation Actually 2022 15,529,138 (9,999,990 ) 11,684,909 17,214,057 2021 14,681,772 (9,999,994 ) 2,888,278 7,570,056 2020 15,724,518 (9,999,970 ) 5,141,773 10,866,321 Year Average Summary Total for Non-PEO NEOs Average Exclusion of Non-PEO Average Inclusion of Non-PEO Average Compensation Non-PEO 2022 3,977,166 (2,074,994 ) 2,523,848 4,426,020 2021 3,740,840 (1,949,990 ) 1,284,616 3,075,466 2020 3,997,258 (2,012,487 ) 1,798,396 3,783,167 The amounts in the Inclusion of Equity Values in the tables above are derived from the amounts set forth in the following tables: Year Year-End Fair Change in Fair Vesting-Date Change in Fair Fair Value at Value of Total - Inclusion of 2022 12,225,190 (546,605 ) 0 6,324 0 0 11,684,909 2021 7,614,065 (5,298,346 ) 0 572,559 0 0 2,888,278 2020 8,077,067 (2,209,566 ) 0 (725,728 ) 0 0 5,141,773 Year Average Year- End Fair Value Non-PEO Average Non-PEO Average Vesting-Date Non-PEO Average Non-PEO Average Fair Non-PEO Average Value Non-PEO Total - Average Non-PEO 2022 2,536,721 9,389 0 (22,262 ) 0 0 2,523,848 2021 1,484,735 (409,621 ) 0 209,502 0 0 1,284,616 2020 1,680,018 36,926 0 81,452 0 0 1,798,396 (4) The Peer Group TSR set forth in this table utilizes the Dow Jones U.S. Select Pharmaceuticals Index, which we also utilize in the stock performance graph required by Item 201(e) of Regulation S-K (5) We determined Non-GAAP Non-PEO Non-GAAP
Company Selected Measure Name	Non-GAAP Operating Profit
Named Executive Officers, Footnote [Text Block]	2020 2021 2022 Eli Kalif Eli Kalif Eli Kalif Dr. Hafrun Fridriksdottir Dr. Sven Dethlefs Dr. Sven Dethlefs Brendan O’Grady Eric Drapé Mark Sabag Eric Drapé Mark Sabag Eric Drapé
Peer Group Issuers, Footnote [Text Block]	The Peer Group TSR set forth in this table utilizes the Dow Jones U.S. Select Pharmaceuticals Index, which we also utilize in the stock performance graph required by Item 201(e) of Regulation S-K
PEO Total Compensation Amount	$ 15,529,138	$ 14,681,772	$ 15,724,518
PEO Actually Paid Compensation Amount	$ 17,214,057	7,570,056	10,866,321
Adjustment To PEO Compensation, Footnote [Text Block]	Year Summary Compensation Exclusion of Stock Inclusion of Equity Compensation Actually 2022 15,529,138 (9,999,990 ) 11,684,909 17,214,057 2021 14,681,772 (9,999,994 ) 2,888,278 7,570,056 2020 15,724,518 (9,999,970 ) 5,141,773 10,866,321
Non-PEO NEO Average Total Compensation Amount	$ 3,977,166	3,740,840	3,997,258
Non-PEO NEO Average Compensation Actually Paid Amount	$ 4,426,020	3,075,466	3,783,167
Adjustment to Non-PEO NEO Compensation Footnote [Text Block]	Year Average Summary Total for Non-PEO NEOs Average Exclusion of Non-PEO Average Inclusion of Non-PEO Average Compensation Non-PEO 2022 3,977,166 (2,074,994 ) 2,523,848 4,426,020 2021 3,740,840 (1,949,990 ) 1,284,616 3,075,466 2020 3,997,258 (2,012,487 ) 1,798,396 3,783,167
Compensation Actually Paid vs. Total Shareholder Return [Text Block]	Description of Relationship Between PEO and Non-PEO The following graph sets forth the relationship between Compensation Actually Paid to our PEO, the average of Compensation Actually Paid to our Non-PEO
Compensation Actually Paid vs. Net Income [Text Block]	Description of Relationship Between PEO and Non-PEO The following graph sets forth the relationship between Compensation Actually Paid to our PEO, the average of Compensation Actually Paid to our Non-PEO
Compensation Actually Paid vs. Company Selected Measure [Text Block]	Description of Relationship Between PEO and Non-PEO Non-GAAP The following graph sets forth the relationship between Compensation Actually Paid to our PEO, the average of Compensation Actually Paid to our Non-PEO Non-GAAP
Total Shareholder Return Vs Peer Group [Text Block]	Description of Relationship Between Company TSR and Peer Group TSR The following graph compares our cumulative TSR over the three most recently completed fiscal years to that of the Dow Jones U.S. Select Pharmaceuticals Index over the same period.
Tabular List [Table Text Block]	Tabular List of Most Important Financial Performance Measures The following table presents the financial performance measures that the Company considers to have been the most important in linking Compensation Actually Paid to our PEO and other NEOs for fiscal year 2022 to Company performance. The performance measures included in this table are not ranked by relative importance. Most Important Performance Measures Non-GAAP Net Revenue Relative TSR Non-GAAP Free Cash Flow
Total Shareholder Return Amount	$ 93.06	81.73	98.47
Peer Group Total Shareholder Return Amount	123.43	129.31	114.32
Net Income (Loss)	$ (2,406,000,000)	$ 456,000,000	$ (4,099,000,000)
Company Selected Measure Amount	4,139,000,000	4,401,000,000	4,388,000,000
PEO Name	Kåre Schultz
Measure [Axis]: 1
Pay vs Performance Disclosure [Table]
Measure Name	Non-GAAP Operating Profit
Non-GAAP Measure Description [Text Block]	We determined Non-GAAP Non-PEO Non-GAAP
Measure [Axis]: 2
Pay vs Performance Disclosure [Table]
Measure Name	Net Revenue
Measure [Axis]: 3
Pay vs Performance Disclosure [Table]
Measure Name	Relative TSR
Measure [Axis]: 4
Pay vs Performance Disclosure [Table]
Measure Name	Non-GAAP Earnings Per Share
Measure [Axis]: 5
Pay vs Performance Disclosure [Table]
Measure Name	Free Cash Flow
PEO [Member] \| Exclusion of Stock Awards and Option Awards [Member]
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount	$ (9,999,990)	$ (9,999,994)	$ (9,999,970)
PEO [Member] \| Inclusion of Equity Values [Member]
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount	11,684,909	2,888,278	5,141,773
PEO [Member] \| YearEnd Fair Value of Equity Awards Granted During Year That Remained Unvested as of Last Day of Year [Member]
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount	12,225,190	7,614,065	8,077,067
PEO [Member] \| Change in Fair Value from Last Day of Prior Year to Last Day of Year of Unvested Equity Awards [Member]
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount	(546,605)	(5,298,346)	(2,209,566)
PEO [Member] \| VestingDate Fair Value of Equity Awards Granted During Year that Vested During Year [Member]
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount	0	0	0
PEO [Member] \| Change in Fair Value from Last Day of Prior Year to Vesting Date of Unvested Equity Awards that Vested During Year [Member]
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount	6,324	572,559	(725,728)
PEO [Member] \| Fair Value at Last Day of Prior Year of Equity Awards Forfeited During Year [Member]
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount	0	0	0
PEO [Member] \| Value of Dividends or Other Earnings Paid on Equity Awards Not Otherwise Included [Member]
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount	0	0	0
Non-PEO NEO [Member] \| Exclusion of Stock Awards and Option Awards [Member]
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount	(2,074,994)	(1,949,990)	(2,012,487)
Non-PEO NEO [Member] \| Inclusion of Equity Values [Member]
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount	2,523,848	1,284,616	1,798,396
Non-PEO NEO [Member] \| YearEnd Fair Value of Equity Awards Granted During Year That Remained Unvested as of Last Day of Year [Member]
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount	2,536,721	1,484,735	1,680,018
Non-PEO NEO [Member] \| Change in Fair Value from Last Day of Prior Year to Last Day of Year of Unvested Equity Awards [Member]
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount	9,389	(409,621)	36,926
Non-PEO NEO [Member] \| VestingDate Fair Value of Equity Awards Granted During Year that Vested During Year [Member]
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount	0	0	0
Non-PEO NEO [Member] \| Change in Fair Value from Last Day of Prior Year to Vesting Date of Unvested Equity Awards that Vested During Year [Member]
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount	(22,262)	209,502	81,452
Non-PEO NEO [Member] \| Fair Value at Last Day of Prior Year of Equity Awards Forfeited During Year [Member]
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount	0	0	0
Non-PEO NEO [Member] \| Value of Dividends or Other Earnings Paid on Equity Awards Not Otherwise Included [Member]
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount	$ 0	$ 0	$ 0